The remaining mispredictions included 3 ACE inhibitors and 2 BTK inhibitors, both of which are peripherally associated with HCV through liver fibrosis mitigation and HCV reactivation, respectively.32,33 Beyond showing its power, this example suggests that functional label-guided drug discovery may serve as an additional approach for antiviral repurposing which could help contribute to mitigating future pandemics. The gene discussed is BTK; the disease is Hepatic fibrosis.